Literature DB >> 25288579

Do diabetic foot infections with methicillin-resistant Staphylococcus aureus differ from those with other pathogens?

Besa Zenelaj1, Cindy Bouvet1, Benjamin A Lipsky2, Ilker Uçkay3.   

Abstract

There is controversy as to whether or not diabetic foot infections (DFIs) caused by methicillin-resistant Staphylococcus aureus (MRSA) are associated with worse outcomes than DFIs caused by other pathogens. To address this issue we performed a nonsystematic literature search of published articles in English language journals seeking studies reporting on the outcomes of DFIs related to their microbiology. We retrieved 48 articles published from 1999 to 2013 that described a total of 7771 cases of DFI. The overall proportion of DFIs with an isolate of S aureus was about 30%; just over one third of these (11% of all cases) were MRSA strains. Among the DFI cases caused by MRSA 1543 were episodes of soft tissue infections and 113 of osteomyelitis, while non-MRSA organisms caused 5761 soft tissue infections and 354 cases of osteomyelitis. Only 5 of the included articles attempted a comparison between DFI caused by MRSA and those caused by other pathogens, with no clear differences noted. The median total duration of antibiotic therapy for DFI caused by MRSA was 26 days, of which a median of 10 days was given intravenously. Only a few articles reported the proportion of patients with a recurrence, but they often did not differentiate between MRSA and non-MRSA cases. Four publications reported a worse functional or microbiological outcome in MRSA, compared to non-MRSA, cases, but the findings were variable and differences did not seem to be significant. Many trials failed to adjust for case-mix or to definitively demonstrate a relationship between microbiology and outcomes. Few of the articles specifically commented on whether the MRSA isolates were health care- or community-acquired strains. Notwithstanding the substantial limitations of the available literature, there does not appear to be a need for any special treatment for DFI caused by MRSA. The current guidelines for treating according to established international recommendations seem appropriate.
© The Author(s) 2014.

Entities:  

Keywords:  MRSA; Staphylococcus aureus; diabetic foot infection; review; treatment

Mesh:

Substances:

Year:  2014        PMID: 25288579     DOI: 10.1177/1534734614550311

Source DB:  PubMed          Journal:  Int J Low Extrem Wounds        ISSN: 1534-7346            Impact factor:   2.057


  17 in total

1.  Neutralizing Alpha-Toxin Accelerates Healing of Staphylococcus aureus-Infected Wounds in Nondiabetic and Diabetic Mice.

Authors:  Roger V Ortines; Haiyun Liu; Lily I Cheng; Taylor S Cohen; Heather Lawlor; Abhishek Gami; Yu Wang; Carly A Dillen; Nathan K Archer; Robert J Miller; Alyssa G Ashbaugh; Bret L Pinsker; Mark C Marchitto; Christine Tkaczyk; C Kendall Stover; Bret R Sellman; Lloyd S Miller
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

2.  Prescribing antibiotics in diabetic foot infection: what is the role of initial microscopy and culture of tissue samples?

Authors:  Robin Chisman; Danielle Lowry; Mujahid A Saeed; Alok Tiwari; Miruna D David
Journal:  Int Wound J       Date:  2016-10-03       Impact factor: 3.315

3.  Moderate to Severe Soft Tissue Diabetic Foot Infections: A Randomized, Controlled, Pilot Trial of Post-debridement Antibiotic Treatment for 10 versus 20 days.

Authors:  Karim Gariani; Jean-Christophe Richard; Benjamin Kressmann; François R Jornayvaz; Jacques Philippe; Benjamin A Lipsky; Ilker Uçkay
Journal:  Ann Surg       Date:  2021-09-15       Impact factor: 13.787

4.  High burden of diabetic foot infections in the top end of Australia: An emerging health crisis (DEFINE study).

Authors:  Robert J Commons; Claire H Robinson; David Gawler; Joshua S Davis; Ric N Price
Journal:  Diabetes Res Clin Pract       Date:  2015-09-21       Impact factor: 5.602

Review 5.  Staphylococcus aureus Toxins and Diabetic Foot Ulcers: Role in Pathogenesis and Interest in Diagnosis.

Authors:  Catherine Dunyach-Remy; Christelle Ngba Essebe; Albert Sotto; Jean-Philippe Lavigne
Journal:  Toxins (Basel)       Date:  2016-07-07       Impact factor: 4.546

6.  The Impact of Multidrug-Resistant Organisms on Outcomes in Patients With Diabetic Foot Infections.

Authors:  Oryan Henig; Jason M Pogue; Emily Martin; Umar Hayat; Mahmoud Ja'ara; Paul E Kilgore; Raymond Cha; Sorab Dhar; Keith S Kaye
Journal:  Open Forum Infect Dis       Date:  2020-05-06       Impact factor: 3.835

7.  Stopping antibiotics after surgical amputation in diabetic foot and ankle infections-A daily practice cohort.

Authors:  Anne Rossel; Dan Lebowitz; Karim Gariani; Mohamed Abbas; Benjamin Kressmann; Mathieu Assal; Philippe Tscholl; Dimitrios Stafylakis; Ilker Uçkay
Journal:  Endocrinol Diabetes Metab       Date:  2019-02-06

8.  Molecular typing, virulence traits and antimicrobial resistance of diabetic foot staphylococci.

Authors:  Carla Mottola; Teresa Semedo-Lemsaddek; João J Mendes; José Melo-Cristino; Luís Tavares; Patrícia Cavaco-Silva; Manuela Oliveira
Journal:  J Biomed Sci       Date:  2016-03-08       Impact factor: 8.410

Review 9.  Microbiology and Antimicrobial Therapy for Diabetic Foot Infections.

Authors:  Ki Tae Kwon; David G Armstrong
Journal:  Infect Chemother       Date:  2018-03

Review 10.  Bacterial Diversity of Diabetic Foot Ulcers: Current Status and Future Prospectives.

Authors:  Fatemah Sadeghpour Heravi; Martha Zakrzewski; Karen Vickery; David G Armstrong; Honghua Hu
Journal:  J Clin Med       Date:  2019-11-10       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.